| Nanocarrier vaccines for SARS-CoV-2 J Machhi, F Shahjin, S Das, M Patel, MM Abdelmoaty, JD Cohen, ... Advanced Drug Delivery Reviews 171, 215-239, 2021 | 94 | 2021 |
| The chemopreventive effect of Ginkgo biloba and Silybum marianum extracts on hepatocarcinogenesis in rats HO El Mesallamy, NS Metwally, MS Soliman, KA Ahmed, ... Cancer cell international 11, 1-12, 2011 | 94 | 2011 |
| CD4+ effector T cells accelerate Alzheimer’s disease in mice J Machhi, P Yeapuri, Y Lu, E Foster, R Chikhale, J Herskovitz, ... Journal of neuroinflammation 18, 1-23, 2021 | 64 | 2021 |
| Synthesis, biological evaluation, and metabolic stability of phenazine derivatives as antibacterial agents M Krishnaiah, NR de Almeida, V Udumula, Z Song, YS Chhonker, ... European Journal of Medicinal Chemistry 143, 936-947, 2018 | 49 | 2018 |
| A role for extracellular vesicles in SARS-CoV-2 therapeutics and prevention J Machhi, F Shahjin, S Das, M Patel, MM Abdelmoaty, JD Cohen, ... Journal of Neuroimmune Pharmacology 16, 270-288, 2021 | 46 | 2021 |
| Defining the innate immune responses for SARS-CoV-2-human macrophage interactions MM Abdelmoaty, P Yeapuri, J Machhi, KE Olson, F Shahjin, V Kumar, ... Frontiers in immunology 12, 741502, 2021 | 41 | 2021 |
| Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease KE Olson, KL Namminga, Y Lu, AD Schwab, MJ Thurston, ... EBioMedicine 67, 2021 | 30 | 2021 |
| Europium-doped cerium oxide nanoparticles for microglial amyloid beta clearance and homeostasis J Machhi, P Yeapuri, M Markovic, M Patel, W Yan, Y Lu, JD Cohen, ... ACS chemical neuroscience 13 (8), 1232-1244, 2022 | 17 | 2022 |
| Local renin-angiotensin system regulates the differentiation of mesenchymal stem cells into insulin-producing cells through angiotensin type 2 receptor NA Sadik, NS Metwally, OG Shaker, MS Soliman, AA Mohamed, ... Biochimie 137, 132-138, 2017 | 16 | 2017 |
| Development of an extended half-life GM-CSF fusion protein for Parkinson's disease P Yeapuri, KE Olson, Y Lu, MM Abdelmoaty, KL Namminga, M Markovic, ... Journal of Controlled Release 348, 951-965, 2022 | 13 | 2022 |
| Monocyte biomarkers define sargramostim treatment outcomes for Parkinson's disease MM Abdelmoaty, J Machhi, P Yeapuri, F Shahjin, V Kumar, KE Olson, ... Clinical and Translational Medicine 12 (7), e958, 2022 | 13 | 2022 |
| Multipolymer microsphere delivery of SARS-CoV-2 antigens F Shahjin, M Patel, J Machhi, JD Cohen, MU Nayan, P Yeapuri, C Zhang, ... Acta Biomaterialia 158, 493-509, 2023 | 9 | 2023 |
| Amyloid-β specific regulatory T cells attenuate Alzheimer’s disease pathobiology in APP/PS1 mice P Yeapuri, J Machhi, Y Lu, MM Abdelmoaty, R Kadry, M Patel, S Bhattarai, ... Molecular neurodegeneration 18 (1), 97, 2023 | 6 | 2023 |
| An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers KE Olson, MM Abdelmoaty, KL Namminga, Y Lu, H Obaro, P Santamaria, ... Translational Neurodegeneration 12 (1), 26, 2023 | 6 | 2023 |
| Preliminary preclinical study of Chol-DsiRNA polyplexes formed with PLL [30]-PEG [5K] for the RNAi-based therapy of breast cancer Z Ye, MM Abdelmoaty, VV Ambardekar, SM Curran, SR Dyavar, LL Arnold, ... Nanomedicine: Nanotechnology, Biology and Medicine 33, 102363, 2021 | 5 | 2021 |
| Clinical biomarkers for Lewy body diseases MM Abdelmoaty, E Lu, R Kadry, EG Foster, S Bhattarai, RL Mosley, ... Cell & Bioscience 13 (1), 209, 2023 | 4 | 2023 |
| Immune senescence in aged APP/PS1 mice MM Abdelmoaty, P Yeapuri, J Machhi, Y Lu, KL Namminga, R Kadry, E Lu, ... NeuroImmune Pharmacology and Therapeutics 2 (3), 317-330, 2023 | 1 | 2023 |
| Direct Comparison of Chol-siRNA Polyplexes and Chol-DsiRNA Polyplexes Targeting STAT3 in a Syngeneic Murine Model of TNBC Z Ye, MM Abdelmoaty, SM Curran, SR Dyavar, D Kumar, Y Alnouti, ... Non-coding RNA 8 (1), 8, 2022 | 1 | 2022 |
| Neuroprotective mushrooms MM Abdelmoaty, R Kadry, RL Mosley, HE Gendelman NeuroImmune Pharmacology and Therapeutics, 2024 | | 2024 |
